This clinical trial is focused on studying treatments for high-risk melanoma, a type of skin cancer that has been surgically removed but still poses a risk of returning. The study is comparing two treatments: one is a combination of two medications, pembrolizumab and vibostolimab, known together as MK-7684A, and the other is pembrolizumab alone. Pembrolizumab is a medication that helps the immune system fight cancer cells, while vibostolimab is another drug that works with pembrolizumab to enhance this effect.
The purpose of the study is to see which treatment is more effective in preventing the cancer from coming back. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 12 months, during which time participants will be monitored regularly to check for any signs of the cancer returning and to assess their overall health and well-being.
Throughout the study, researchers will also keep track of any side effects experienced by participants and how these might affect their quality of life. The goal is to gather information that will help determine the best treatment option for people with high-risk melanoma, aiming to improve their chances of staying cancer-free for as long as possible.
Austria 
Belgium 
France 
Germany 
Ireland 
Italy 
Poland 
Spain 
Sweden 
